1
Clinical Trials associated with NeoAg-mBRAFEnhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.
100 Clinical Results associated with NeoAg-mBRAF
100 Translational Medicine associated with NeoAg-mBRAF
100 Patents (Medical) associated with NeoAg-mBRAF
100 Deals associated with NeoAg-mBRAF